These findings raise the question of whether retroviral VEGF gene therapy is useful for therapeutic ‘angiogenesis’ without risking ‘angioma-genesis’. Overexpression of VEGF may lead to an ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that we have completed enrollment ...

Summit Therapeutics Inc. may have a potential successor to Merck's Keytruda with strong clinical data from China, but awaits ...

The first possible competitive advantage might be in terms of VEGF angiogenesis targeting. That is, this drug can target VEGF ligands beyond that of VEGF-A only. This is one possible way of ...

Discover Kodiak Sciences' groundbreaking patent for a dual-action protein construct targeting IL-6 and VEGF, aimed at treating neovascular retinal diseases effectively.

The global Age-related Macular Degeneration drugs market is set to grow from USD 10.46 billion in 2024 to USD 17.37 billion ...

Mum Michelle Freeman, 51, has been given the devastating news that she has just 13 months left to live after being diagnosed ...

In a striking display of market momentum, Summit Therapeutics Inc. (NASDAQ: SMMT) saw its stock price soar by 16.66% to $21.71 during Friday’s premarket trading session. This surge comes on the heels ...

Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and ...

GlobalData’s report assesses the drugs in the Placenta Growth Factor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.